Recursion Pharmaceuticals, Inc. splits its revenue into 2 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was License And Service at $74.3 million, 99% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
|---|---|---|---|---|---|---|
| Revenue |
68
|
75
|
59
|
45
|
40
|
10
|
| License And Service |
67
+54.3%
share 98.2%
|
74
+27.0%
share 99.4%
|
58
+33.3%
share 99.4%
|
44
+10.6%
share 98.4%
|
40
+296.8%
share 99.6%
|
10
share 98.3%
|
| Grant |
1
+347.6%
share 1.8%
|
0
+21.1%
share 0.6%
|
0
-49.8%
share 0.6%
|
1
+331.5%
share 1.6%
|
0
-9.0%
share 0.4%
|
0
share 1.7%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- RXRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1601830
- Former names
- Recursion Pharmaceuticals, LLC (until Dec 4, 2015)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.